Cyclerion Therapeutics, Inc.
CYCNNasdaq
$3.64
↓ -0.5%Jul 17 close · end-of-day
Price
1Y↑ +19.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$15.3M
Enterprise Value
$12.5M
P/E
—
P/S
7.7
P/B
2.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$2.0M
Net Income (TTM)
-$5.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-337.4%
Net Margin
-264.7%
ROE
-77.7%
ROIC
-133.9%
Debt / Equity
—
Net Cash
$2.8M
Return 1Y
+20.5%
Company profile
Cyclerion Therapeutics, Inc. engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
- CEO
- Peter M. Hecht
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- Massachusetts
- Website
- cyclerion.com
Earnings
CYCN Q 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS-$0.76↑ +35.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.3M | $3.9M | $297,000.00 | $0.00 | $2.0M | $2.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$81.3M | -$55.2M | -$18.5M | -$13.0M | -$3.6M | -$5.0M |
| Net income | -$77.8M | -$51.6M | -$44.1M | -$5.3M | -$3.1M | -$3.5M |
| Diluted EPS | — | -$1.32 | -$20.28 | -$2.25 | -$1.21 | -$1.11 |
| Operating cash flow | -$72.5M | -$36.5M | -$40.6M | -$21.2M | -$4.3M | -$3.3M |
| Free cash flow | -$74.0M | -$36.5M | -$40.6M | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -3539.4% | -1400.2% | -6242.4% | — | -181.4% | -239.8% |
| Net margin | -3388.6% | -1310.2% | -14841.1% | — | -152.8% | -170.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $194,000.00 | $1.8M | $81,000.00 | $93,000.00 | $875,000.00 | $1.0M | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.4M | -$1.1M | $502,000.00 | -$1.5M | -$1.7M | -$1.0M | -$838,000.00 | -$3.2M |
| Net income | -$1.3M | -$723,000.00 | $530,000.00 | -$1.4M | -$324,000.00 | -$976,000.00 | -$799,000.00 | -$3.2M |
| Diluted EPS | -$0.53 | -$0.29 | $0.23 | -$0.56 | -$0.11 | -$0.30 | -$0.14 | -$0.76 |
| Operating cash flow | -$1.1M | -$1.7M | $360,000.00 | -$968,000.00 | -$503,000.00 | -$264,000.00 | -$1.6M | -$1.2M |
| Free cash flow | — | — | — | -$968,000.00 | — | — | — | -$1.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | -581.4% | 27.8% | -1798.8% | -1797.8% | -115.0% | -81.8% | — |
| Net margin | — | -372.7% | 29.3% | -1764.2% | -348.4% | -111.5% | -78.0% | — |
Company news
Apr 1, 2026
Feb 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.